Tumor necrosis factor alpha (TNF-oa) was discovered as a factor in the serum of mice injected with bacillus CalmetteGuerin (Mycobacterium bovis BCG) or lipopolysaccharide that induced tumor necrosis in tumor-bearing mice (16) . A similar factor, TNF-3 (lymphotoxin), was discovered as a soluble factor released from the lymph node T cells of immunized rats that shows cytolytic activity toward murine L929 fibroblasts (59) . Subsequent studies have led to the molecular cloning of the two related factors, TNF-ot and TNF-13, that have similar actions in vivo and in vitro (26) . These TNFs are potent cytokines that elicit a large number of biological effects, including hemorrhagic necrosis of transplanted tumors, cytotoxicity, immunoregulation, cellular proliferation, antiviral responses, and transcriptional activation of many genes (9, 24, 26) . In particular, TNF-ao has an important role in the inflammatory response and is a principal mediator of toxic shock and sepsis.
The primary source of TNF-ot is the activated macrophage or monocyte, while activated T cells represent the major source of TNF-4. Although these factors are released from different cell types, both TNF-ot and TNF-r3 bind to the same two cell surface receptors (55 and 75 kDa) that are widely expressed in the tissues of the body (70) . The extracellular domains of these receptors share 28% homology and are divided into four repeating Cys-rich domains, similar to the low-affinity nerve growth factor receptor, Fas antigen, CD40, OX40, and CD27 (68) . In contrast, the cytoplasmic domains of the two TNF receptors have no obvious homology to each other (70) . This has led to some controversy about the role of each receptor (34, 72) . However, a consensus view is that the 55-kDa receptor mediates cytotoxicity, antiviral activity, fibroblast proliferation, and transcription factor activation (13, 21, 22, 47, 68-70, 72, 73, 76, 77) . The 75-kDa receptor may mediate a distinct signaling role (35, 42) . Alternatively, the 75-kDa * Corresponding author.
receptor may act as a coreceptor that presents TNF for binding the 55-kDa signaling receptor (71) .
The structure of TNF bound to the 55-kDa receptor has been determined by X-ray crystallography to consist of three receptor molecules bound symmetrically to one TNF-f3 trimer (8) . This structure suggests that TNF-induced aggregation of the 55-kDa receptor may represent an initial step in the signal transduction mechanism. Interestingly, ligand-induced aggregation has been established to account for the activation of tyrosine kinase receptors (60) . Receptor aggregation may therefore be a common mechanism of activation of several classes of cell surface receptors.
The mechanism of signal transduction by TNF receptors is poorly understood. However, it is likely that the TNF signaling mechanism is similar to that of the proinflammatory cytokine interleukin-1 (IL-1). Both of these cytokines cause marked activation of transcription factors AP-1 and NF-KB (14, 46, 51) . In addition, the analysis of cellular phosphoproteins by twodimensional gel electrophoresis demonstrates that TNF and IL-1 cause increased phosphorylation of a common group of at least 53 proteins and decreased phosphorylation of 10 additional proteins (31) . Treatment of cells with other cytokines does not regulate the phosphorylation of the same group of proteins, indicating that TNF may activate a distinct signal transduction pathway. Examples of TNF-stimulated phosphorylation include the 27-to 28-kDa small heat shock proteins, the 28-kDa mRNA cap-binding protein, the epidermal growth factor (EGF) receptor, eIF-4E, 1-plastin, myosin light chain, nucleolin, stathmin, c-Abl, Rb, and p53 (11, (29) (30) (31) 55) .
Several kinase activities have been reported to be increased by TNF and IL-1. These include well-defined protein kinases, such as protein kinase A (64, 79) , protein kinase C (14, 53) , and mitogen-activated protein (MAP) kinases (ERKs) (28, 31, 57, 74) . As these protein kinases have been implicated in the mechanisms of signal transduction by many other extracellular stimuli, it is difficult to understand how the activation of these kinases can account for the distinctive pattern of protein phosphorylation that is induced by TNF (31) . Therefore, there has been much interest in the role of novel protein kinases. Indeed, several protein kinase activities that are increased by treatment of cells with proinflammatory cytokines have been identified: a ceramide-activated protein kinase (20, 40, 48, 49) , an hsp27 kinase (28), a P-casein kinase (28) , an 85-kDa nuclear kinase (56) , and tyrosine kinase activity (37, 40) . However, these activities have not been molecularly characterized.
The purpose of this study was to investigate whether JNK protein kinases are activated in TNF-treated cells. Two JNK protein kinase isoforms (46 and 55 kDa) have been identified in HeLa cells (36) . Recently, we described the molecular cloning of the 46-kDa isoform, JNK1 (18) . In this report, we describe the cloning of the 55-kDa isoform, JNK2. In addition, we show that TNF, like UV radiation, causes JNK protein kinase activation. The activation of transcription factor AP-1 caused by UV radiation is similar to that caused by proinflammatory cytokines (14, 19, 51) . The effect on AP-1 can be accounted for by the JNK protein kinase pathway and the phosphorylation of c-Jun within the NH2-terminal activation domain (18, 36 [10 ,uCi/nmol]). The phosphorylation reactions were terminated after 10 min by the addition of Laemmli sample buffer. The phosphorylated proteins were resolved by SDS-PAGE, visualized by autoradiography, and quantitated by Phosphorlmager (Molecular Dynamics Inc.) analysis. Control experiments demonstrated that the phosphorylation reactions were linear with time for at least 40 min. Phosphoamino acid analysis and tryptic peptide mapping were performed as described previously (18) .
Western. blot analysis. Immunoblotting was performed by using Immobilon-P membranes (Millipore Corp.), probing with monoclonal antibody M2, and enhanced chemiluminescence detection (Amersham Inc.) as described previously (18) .
Complementation assays. The HOG1 expression vector pJB17 and Saccharomyces cerevisiae JBY10 (null mutant hoglAl) were obtained from M. Gustin (15) . Expression vectors for JNK1 and JNK2 were constructed by subcloning the cDNAs at the BamHI and HindIII sites of pVP16 (75) . The structure of each plasmid was confirmed by automated sequencing with an Applied Biosystems model 373A machine. Strain JBY10 was transformed with the plasmids, and equal portions were spread on agar plates supplemented without and with 0.9 M NaCl. Expression of JNK1 and JNK2 in the yeast cells was confirmed in control experiments by Western blot analysis.
Nucleotide sequence accession number. The sequence of the human JNK2 cDNA has been deposited in the GenBank database with accession number L31951.
RESULTS
The JNK group of protein kinases includes JNK1 and JNK2. We have identified a 46-kDa protein kinase as a member of the JNK protein kinase group (18) . To identify additional members of this group, we screened a HeLa cDNA VOL. 14, 1994 on (Fig. 1) . Comparison of the nucleotide sequences of JNK1 and JNK2 indicates that these protein kinases are the products of distinct genes. However, comparison of the deduced protein sequence of JNK1 and JNK2 indicates a high level of sequence identity within the protein kinase domain (Fig. 1B) . Significantly, these JNK isoforms share the Thr-183-Pro-Tyr-185 motif that corresponds to the activating Thr and Tyr phosphorylation sites of JNK1 (18) . Several amino acid differences between JNK1 and JNK2 are located within the kinase domain. However, the most obvious difference between these protein kinases is that JNK2 has a larger COOH-terminal extension than JNK1 (Fig. 1B) .
To examine the expression of the JNK isoforms, we performed Northern blot analysis of mRNA isolated from different human tissues. Isoform-specific probes were prepared from nonhomologous regions of the JNK1 and JNK2 cDNAs (3' untranslated region). A low level of expression of JNK1 and JNK2 was observed in human brain, heart, kidney, lung, pancreas, and skeletal muscle (data not shown). Together, these data indicate that the JNK1 and JNK2 protein kinases are widely expressed in human tissues. Fig. 2A) . A higher level of expression of JNK1 than of JNK2 was observed in the transient transfection assays. This difference in the level of expression was confirmed in control experiments by immunoprecipitation of the JNK isoforms from cells metabolically labeled with [35S]methionine (data not shown).
JNK protein kinase activity was measured by immunoprecipitation of the recombinant JNK proteins with monoclonal antibody M2. It was found that both JNK isoforms phosphorylated the NH2-terminal activation domain of c-Jun (Fig. 2B) . Exposure of the cells to UV radiation caused a marked increase in JNK protein kinase activity. Interestingly, the phosphorylation of c-Jun caused by JNK2 was more efficient than that caused by JNK1. Quantitation of these data by Phosphorlmager analysis demonstrated that the specific activity of JNK2 was approximately 10-fold greater than that of JNK1.
JNK1 and JNK2 protein kinases phosphorylate c-Jun at Ser-63 and Ser-73. The increased phosphorylation of c-Jun observed in experiments using JNK2 compared with JNK1 may result from the phosphorylation of different sites by these protein kinases. We therefore examined the sites of c-Jun phosphorylation by JNK1 and JNK2 by phosphoamino acid analysis and tryptic phosphopeptide mapping. Both protein kinases were found to phosphorylate c-Jun exclusively on Ser Phosphorlmager analysis demonstrated that JNK2 binding was approximately 10-fold greater than JNK1 binding. The specificity of binding was examined by comparing the interaction of JNK protein kinases with c-Jun and v-Jun. In previous studies, it has been demonstrated that v-Jun has a deletion in the 8 subregion of the activation domain that markedly reduces binding to JNK protein kinases (2-4, 18, 36) . GST fusion proteins with c-Jun and v-Jun were immobilized on GSH-agarose and incubated with cell extracts containing epitope-tagged JNK1 or JNK2. The agarose beads were washed, and the bound JNK protein kinases were detected by Western blot analysis using monoclonal antibody M2. Figure  4B shows that v-Jun is defective in binding both JNK isoforms.
Together, these data demonstrate that JNK1 and JNK2 bind to the NH2-terminal activation domain of c-Jun but not to v-Jun. The increased c-Jun phosphorylation caused by JNK2 (Fig. 2) correlates with increased binding of c-Jun to JNK2 compared with JNK1 (Fig. 4A) .
Selective complementation of a deficiency in HOG1 expression by JNK protein kinases. Comparison of the sequence of human JNK1 with the GenBank database indicates that this enzyme is similar to the S. cerevisiae MAP kinase HOG1 (18) . This similarity suggests that HOG1 and JNK protein kinases may serve similar functions in yeast and mammalian cells, ( Fig. 3A) . The tryptic phosphopeptide maps of c-Jun phosphorylated by JNK1 and JNK2 were similar. The two phosphopeptides observed have previously been demonstrated to correspond to the phosphorylation of c-Jun at Ser-63 and Ser-73 (7, 18, 54, 65, 66 respectively. To test this hypothesis, we examined whether human JNK1 or JNK2 is able to complement a deficiency in HOG1 expression. Yeast cells lacking HOG1 (null mutant hogl-Al) are sensitive to osmotic stress and do not grow on high-osmolarity media (15) . Transfection of the hogl-Al mutant with an expression vector encoding HOG1 rescues this growth defect (Fig. 5) . The hogl-Al mutant was not rescued by transfection with an expression vector encoding the human MAP kinase ERK2 (25) . However, the hogl-Al mutant was rescued when the cells were transfected with a JNK1 expression vector (Fig. 5) . The specificity of the complementation by JNK1 was confirmed by the demonstration that catalytically inactive JNK1 (Thr-183-Pro-Tyr-185) substituted with Ala-183-Pro-Phe-185 [18] ) did not complement the hogl-Al mutant (25) . The complementation by wild-type JNK1 indicates that this kinase can functionally substitute for HOG1 in yeast cells (25) . In contrast, it was found that JNK2 did not complement the hogl-Al mutant (Fig. 5) . Control experiments using Western blot analysis demonstrated that both JNK isoforms were expressed in yeast cells. The lack of complementation by JNK2 therefore reflects a difference in the properties of JNK1 and JNK2.
Together, these data demonstrate that human JNK1 (but not JNK2) is able to substitute for the HOG1 protein kinase in yeast cells. This difference in complementation provides evidence that the in vivo functions of JNK1 and JNK2 are distinct. This conclusion is consistent with the observation that these JNK isoforms do not have identical biochemical properties ( Fig. 2 and 4) .
TNF activates the JNK protein kinase signal transduction pathway. UV radiation causes potent activation of JNK protein kinases (Fig. 2) . In contrast, the JNK signal transduction pathway is only modestly activated by growth factors (e.g., EGF), activated Ha-Ras, and phorbol ester (18) . A significant question therefore concerns the identity of physiological inducers of the JNK protein kinase pathway. As JNK activates c-Jun, candidate inducers of the JNK pathway include agents that cause sustained induction of c-Jun, such as the proinflammatory cytokine TNF-ot (14) . We therefore tested the hypothesis that TNF-ot causes JNK activation.
We examined JNK activation in HeLa cells treated with TNF-a. The JNK protein kinases were isolated by immunoprecipitation with a polyclonal JNK antibody, and protein kinase activity in the immunoprecipitates was examined after SDS-PAGE using an in-gel protein kinase assay with c-Jun as a substrate. It was found that TNF-ao activated both the 46-kDa JNK1 and 55-kDa JNK2 protein kinases (Fig. 6) .
The effect of TNF-ot concentration on JNK activation was examined in an immune-complex protein kinase assay with the substrates c-Jun and [-y-32P]ATP. JNK activation was observed when the HeLa cells were incubated with 1.25 ng of TNF-at per ml (Fig. 7) . A further increase in JNK activateon was found when the cells were incubated with higher concentrations of TNF-a. The time course of JNK activation was investigated in experiments using HeLa cells incubated with 10 ng of TNF-a per ml. A rapid and marked increase in JNK activity within 15 min of treatment with TNF-a was observed (Fig. 8) . JNK activity then declined to control levels 30 min after TNF-at treatment. A lower but sustained increase in JNK activity was observed at later times of TNF-at treatment. Together, these data establish that the JNK protein kinase pathway is activated by the proinflammatory cytokine TNF-a.
DISCUSSION
Signal transduction by proinflammatory cytokines. One important action of proinflammatory cytokines is the regulation of gene expression. TNF (and IL-1) induce the expression of multiple cytokines, such as colony-stimulating factors, IL-2, IL-6, IL-8, hepatocyte growth factor, TGF-a, nerve growth factor, P-endorphin, and Gro-related factors (23, 32, 33, 41, 52, 58, 67, 78) . TNF has also been shown to induce IL-1 expression (27) . Increased expression of proteins encoded by immediateearly genes (e.g., c-Jun), cytokine receptors (e.g., IL-2 receptor), growth factor receptors (e.g., the EGF receptor), major histocompatibility complex (classes I and II), and collagenase have been reported (14, 42, 58, 61 Recent studies have established a primary role for increased AP-1 activity. Examples include the increased expression of IL-2 (51), P-endorphin (23) , c-Jun (50), the monocyte chemoattractant JE (32) , and the hyaluronan-binding protein TSG6 (45) . Together, these data demonstrate that AP-1 is a physiologically significant target of the signal transduction pathway activated by proinflammatory cytokines.
Homodimers of c-Jun or heterodimers of c-Jun with partner proteins (e.g., c-Fos) bind to AP-1 sites (1, 43) . Significantly, the proinflammatory cytokines TNF and IL-1 cause a marked increase in c-Jun expression (14, 51) . The increased expression of c-Jun is mediated by two cis-acting elements (AP-1 sites) in the c-Jun promoter (50) . This observation indicates that the induction of c-Jun expression is dependent on the activation of preexisting complexes of the AP-1 transcription factor (38) . One mechanism of activation is mediated by the phosphorylation of the NH2-terminal activation domain of c-Jun (10). Indeed, detailed studies have demonstrated that the phosphorylation of c-Jun within the NH2-terminal domain at Ser-63 and Ser-73 causes increased transcriptional activity (54, 65, 66) . These regulatory sites of phosphorylation are substrates for JNK protein kinases (36) . Two JNK protein kinase isoforms (46 and 55 kDa) have been identified in HeLa cells (36) . Recently, we molecularly cloned the 46-kDa isoform, JNK1 (18) . Here, we describe the cloning of the 55-kDa isoform, JNK2.
As JNK protein kinases phosphorylate sites on c-Jun that increase transcriptional activity, JNK activation provides a signaling mechanism that regulates AP-1. Thus, the increased AP-1 activity observed in TNF-treated cells may be mediated by the JNK signal transduction pathway. Consistent with this hypothesis, incubation of cells with TNF caused a marked increase in JNK protein kinase activity (Fig. 6) . Interestingly, JNK activation was also observed when cells were incubated with IL-1 (17a).
Regulation of the JNK group of protein kinases. The JNK group of protein kinases includes the 46-kDa JNK1 and the 55-kDa JNK2 isoforms (Fig. 1) . Rat homologs of human JNK1 and JNK2 have recently been reported as a and -y SAPK (44) . The JNK group of protein kinases are distantly related to the MAP kinases ERK1 and ERK2 (18) . One significant similarity between ERK and JNK is that activation requires dual phosphorylation at Thr and Tyr within subdomain VIII (18) . Interestingly, the phosphorylation motif present in JNK (ThrPro-Tyr) is distinct from that of ERK (Thr-Glu-Tyr). Similarly, the kinase kinases that activate JNK and ERK are distinct (18) . This finding implies that JNK and ERK are located within separate signal transduction pathways. Thus, UV radiation causes potent activation of JNK and only modest changes in ERK activity (18) . In contrast, EGF, activated Ha-Ras, and phorbol ester cause marked ERK activation but only a small increase in JNK activity (18) . Here we demonstrate that the JNK group of protein kinases are activated by the proinflammatory cytokine TNF. A similar conclusion has recently been reported by Kyriakis et al. (44) .
It is possible that JNK1 and JNK2 have redundant functions in the cell. However, the observation that JNK1, but not JNK2, complements a defect in the expression of the HOG1 MAP kinase in S. cerevisiae demonstrates that these JNK isoforms have distinct properties in vivo. Evidence for distinct functions of JNK1 and JNK2 was also obtained by comparison of the in vitro biochemical properties of these JNK isoforms. Thus, the binding of c-Jun to JNK2 was significantly greater than the binding to JNK1 (Fig. 4) . Similarly, JNK2 caused greater phosphorylation of c-Jun than did JNK1 (Fig. 2) . The structural differences between JNK1 and JNK2 that may account for these properties include (i) changes in the protein kinase domain and (ii) the divergent COOH-terminal sequences (Fig.  1B) .
Together, these data suggest that the catalytic activity of JNK2 is greater than that of JNK1. However, it is also possible that these data reflect a difference in the substrate specificity of these JNK isoforms. Thus, c-Jun may be a preferential physiological substrate for JNK2, while JNK1 targets a different substrate. The identification of additional JNK substrates will be required to test this hypothesis. Although it is likely that several substrates for JNK protein kinases exist, at present c-Jun is the only substrate that has been identified (18, 44) . An important goal for future studies will be to identify additional JNK substrates. A comparison of the phosphorylation of these substrates by JNK1 and JNK2 will be necessary to resolve whether the difference in c-Jun phosphorylation by these isoforms is the result of a difference in catalytic activity or substrate specificity.
Conclusions 
